| Who | With | What | Scoop |
|---|---|---|---|
| Invitrogen | Applera's Applied Biosystems | $6.7B merger | Invitrogen has agreed to acquire all of the shares of Applera's Applied Biosystems in a $6.7 billion cash and stock deal. The companies are two of the biggest suppliers to the drug development business. |
| Roche | ThromboGenics and BioInven | $774M deal | In the deal, ThromboGenics gets a whopping $77.4 million upfront payment from Roche, with close to $700 million in milestones that will be split 60/40 between ThromboGenics and BioInvent. |
| Boehringer Ingelheim | Actimis Pharmaceuticals | $515M buyout | Boehringer is buying Actimis Pharmaceuticals, which is developing asthma and allergy drugs. |
| Kyowa Hakko | Alnylam Pharmaceuticals | $93M development pact | Cambridge, MA-based Alnylam will develop an Respiratory Syncytial Virus therapy for Asian markets. |
| Parexel | ClinPhone | $182M buyout | CRO Parexel has made a $182 million bid for U.K.-based ClinPhone, but it may be facing competition from Quintiles, the world's largest private CRO. |
| Stiefel Laboratories | Barrier Therapeutics | $148M buyout | Barrier Therapeutics is a developer of dermatology products. |
Roche inks $774M pact